KemPharm/ZVRA

$6.95

1.16%
-
1D1W1MYTD1YMAX

About KemPharm

Zevra Therapeutics, Inc. is a rare disease company melding science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA. Its pipeline also includes EDSIVO and others.

Ticker

ZVRA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Neil Mcfarlane

Employees

36

Headquarters

Celebration, United States
Website
zevra.com

KemPharm Metrics

BasicAdvanced
$285M
Market cap
-
P/E ratio
-$1.16
EPS
1.82
Beta
-
Dividend rate

What the Analysts think about KemPharm

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
162.59% upside
High $24.00
Low $12.00
$6.95
Current price
$18.25
Average price target

KemPharm Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-500% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$2.8M
-66.67%
Net income
$-14M
180%
Profit margin
-500%
740.05%

KemPharm Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 34.45%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.26
-$0.34
-$0.15
-$0.40
-
Expected
-$0.17
-$0.23
-$0.34
-$0.30
-$0.28
Surprise
50%
46.24%
-56.31%
34.45%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell KemPharm stock

Buy or sell KemPharm stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing